You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development and testing of a digitally assisted risk reduction platform for youth at high risk for suicide
SBC: KSANA HEALTH INC Topic: 104ABSTRACTDespite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Although promising approaches are available for preventative interventions with youth at-risk for suicide, they demonstrate modest benefit, and recent reviews have concluded that new developments are required that facilitate not only greater effectiveness, but also enh ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Sourcerer IC: A Web-Based Integrative Multi-Modal Workflow for Epilepsy Surgical Planning
SBC: Brain Electrophysiology Laboratory Company, LLC Topic: 106Abstract The overarching goal of this project is to create software that improves the use of intracranial EEG to qualify patients with medication-resistant epilepsy for neurosurgery. One million people in the US suffer from continual seizures that are not controlled by medication. The current estimate is that half of these could be treated effectively by surgical resection of the epileptic cortica ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Blood-based Test for Identifying Synucleinopathy in Patients with Dementia
SBC: Neurodex Inc Topic: NINDSPROJECT SUMMARY In this Fast Track SBIR application, NeuroDex, Inc. proposes to use its expertise in extracellular vesicle (EV) immunoaffinity isolation to develop a blood test that detects synucleinopathies with high sensitivity, with the long- term goal of helping clinicians identify patients for whom antipsychotic drugs are harmful and contraindicated. Development and commercialization of a sen ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Hybrid ELISA: Simple and specific one-tier assay for Lyme disease
SBC: KEPHERA DIAGNOSTICS LLC Topic: NIAIDAbstract Lyme disease, caused by infection with the spirochete Borrelia burgdorferi or closely related species, is the most common vector-borne disease in the United States, accounting for nearly 500,000 infections per year according to recent public health estimates. It is also one of the few infectious diseases that requires a two-step laboratory testing protocol, comprising a screening assay, t ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
The Development of a Bimodal Walking-Running Prosthetic Foot
SBC: LIBERATING TECHNOLOGIES INC Topic: NICHDPROJECT SUMMARY / ABSTRACT Over the course of this two-year Phase II effort, Liberating Technologies, Inc. (LTI), along with its collaborators at Fillauer Companies and Hanger Clinic, will refine, expand, and test a bimodal walking-running foot that would then be poised to become a viable commercial product that can be reimbursed under the existing L-code reimbursement structure. The goal of this ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Thrombopoietin Targeting in Myeloproliferative Neoplasms
SBC: ARONORA INC Topic: NHLBIProject Summary/Abstract Treatment of patients with myeloproliferative neoplasms (MPNs) is limited to palliative and cytoreductive agents that mitigate proliferative blood counts and their effects. Small molecule selective tyrosine kinase (JAK1/JAK2) inhibitors were also shown to provide modest patient benefit, including reduced symptomatology and improved quality of life. Despite the available th ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer
SBC: PDX PHARMACEUTICALS, INC. Topic: 102Treatment of non-small cell lung cancer (NSCLC) typically, which requires a combination of many highly toxicdrugs and radiation therapy, is not curative. Immune checkpoint inhibitors (ICIs) targeting PD-L1/PD-1 are causing a paradigm shift in NSCLC treatment, yet the 5-year survival rate remains below 20%.This Fast-Track SBIR application aims to develop a novel nano-immunotherapy (termed ARAC - An ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Software Platform for Automatic, Opportunistic Screening of Vertebral Compression Fractures
SBC: BIOSENSICS LLC Topic: NIAPROJECT SUMMARY / ABSTRACTVertebral compression fracture (VCF) is the most common type of osteoporotic fracture. VCF burdens include, but are not limited to pain, functional impairment, increased risk of future fractures, medical costs and mortality. Only 1/3 of osteoporotic VCFs are symptomatic, and the remaining cases are found incidentally, thus, the burden of VCF disease is significantly under ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Validation of artificial intelligence (AI) based software as medical device (SaMD) for retinopathy of prematurity (ROP)
SBC: Siloam Vision, Inc. Topic: NEIThe purpose of this application is to perform the necessary clinical studies to seek regulatory approval for an artificial intelligence (AI) software as medical device (SaMD) for retinopathy of prematurity (ROP) diagnosis. ROP is a leading cause of childhood blindness worldwide, with approximately 50,000 babies going blind annually, most of which is preventable with accurate and timely diagnosis. ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Dual-Targeting ClpP Activating Antibiotic
SBC: ARIETIS CORPORATION Topic: NIAIDThe World Health Organization has declared that antimicrobial resistance is one of the biggest threats to global health. It was estimated that by 2050, deaths due to drug resistant bacteria will exceed those caused by cancer. The goal of this project is to develop a new ureadepsipeptide antibiotic (UDEP) to treat infections caused by Gram-positive pathogens, such as bacteremia, pneumonia, endocard ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health